µ²ºc¦¡ |
|
Lenalidomide 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Lenalidomide ¬°thalidomide ªº類¦üª«¡A¨ã§K¬Ì½Õ¸`¡B§Ü¦åºÞ·s¥Í¤Î§Ü¸~½F·s¥Íªº¯S½è¡C©óÅ餺¸ÕÅç¡ALenalidomide §í¨î¦hµo©Ê°©Åè½Fªº¬Y¨Ç²ÓM¼W¥Í¨Ã»¤µo¬r殺²ÓM(apoptosis)¡C©ó¬Y¨Ç¥]§t¦hµo©Ê°©Åè½Fªº³y¦å¸~½F¼Ò«¬臨§É«eÅ餺¸ÕÅç¡ALenalidomide ©µ¿ðÀù²ÓM¥Íªø¡CLenalidomide §K¬Ì½Õ¸`¯S©Ê¥]§t¬¡¤ÆT ²ÓM¤Î¦ÛµM殺¤â²ÓM¡A¼W¥[¦ÛµM¬r殺T ²ÓMªº數量¡A¤Î§í¨î³æ®Ö²yªº«Pµoª¢¦]¤l(§YTNF »PIL-6)¡C©ó¦hµo©Ê°©Åè½F²ÓM¡A¦X¨Ö¨Ï¥ÎLenalidomide »Pdexamethasone ·|¥[±j§í¨î²ÓM¼W¥Í¤Î»¤µo¬r殺²ÓMµ¥§@¥Î¡C
|
¾AÀ³¯g |
|
Lenalidomide»Pdexamethasone¦X¨Ö¨Ï¥Î¥iªvÀø¥ý«e¤w±µ¨ü¦Ü¤Ö¤@ºØªvÀø¥¢±Ñ¤§¦hµo©Ê°©Åè½F(multiple myloma, MM)±wªÌ¡C Lenalidomide»Pdexamethasone¦X¨Ö¨Ï¥Î¥iªvÀø¥ý«e©|¥¼±µ¨ü¹L¥ô¦óªvÀø¥B¤£¾A¦X²¾´Ó¤§¦hµo©Ê°©Åè½F±wªÌ¡C
|
¥Îªk¥Î¶q |
|
¥»«~À³©ó¨C¤Ñªº©T©w®É¶¡ªA¥Î¡A¥i³æ¿WªA¥Î©Î»P¹ª«¨ÖªA¡C ¥»ÃÄÀ³¾ã²É¥H¤ô°eªA¡C½¦Ån¤£À³¥´¶}¡B¥´¯}©Î©CÄZ¡Cƒå ¦hµo©Ê°©Åè½F ¥ý«e´¿±µ¨üªvÀø¤§¦hµo©Ê°©Åè½F«Øij°_©l¾¯¶q¬°¨C¤é25²@§J¡A¥H¤ô°eªA¡A¦b28¤Ñ¥ÎÃĶg´Áªº²Ä1¦Ü21¤Ñ¡A¨C¤éªA¥Î1Áû25²@§J½¦Ån¡C¦Ódexamethasoneªº«Øij¾¯¶q¬°¨C¤é40²@§J¡A¦b³Ìªìªº4Ó¥ÎÃĶg´Á¤¤¡A¦b28¤Ñ¥ÎÃĶg´Áªº²Ä1¦Ü4¤Ñ¡B²Ä9¦Ü12¤Ñ¡B²Ä17¦Ü20¤Ñ¨C¤éªA¥Î¡A±µ¤U¨Óªº¥ÎÃĶg´Á«h¥u»Ý¦b28¤Ñ¥ÎÃĶg´Áªº²Ä1¦Ü4¤Ñ¨C¤éªA¥Î40²@§J¡C¦hµo©Ê°©Åè½F¤§¨ä¥L¬r©Ê ¸g§PÂ_»PLenalidomide ¬ÛÃöªº¨ä¥L²Ä3/4¯Å¬r©Ê¡AÀ³¼È°±ªvÀø¡A«Ý¬r©Ê½w¸Ñ¦Ü²Ä2¯Å¥H¤U¡A¥ÑÂå®v§P©w¥H¤U¤@Ó¸û§C¾¯¶q«ì´_ªvÀø¡C
|
ÃİʤO¾Ç |
|
§l¦¬ ¤fªA§ë¤©Lenalidomide «á¡A§l¦¬¨³³t¡CLenalidomide ¤§³æ¦¸¾¯量¤Î¦h¦¸¾¯量§ë¤©¦hµo©Ê°©Åè½F±wªÌ¤§³Ì¤j¦å¤¤¿@度¥X²{¦bµ¹Ãī᪺0.5 ¦Ü6 ¤p®É¶¡¡Clenalidomide ©ó³æ¦¸¾¯量¤Î¦h¦¸¾¯量µ¹Ãī᪺ÃĪ«°Ê力¾Ç¯S©Ê§e½u©Ê¡A¥þ¨暴露量(AUC)¤Î¦å¤¤³Ì°ª¿@度(Cmax)¬Ò»P¾¯量§e¤ñ例¼W¥[¡C«Øij¾¯量ªº¦h¦¸µ¹ÃĨõL³y¦¨ÃĪ«»W¿n¡C Lenalidomide ©óµÇ¥\¯à¥¿±`©Î»´度°IºÜ(CLcr ≥ 60 mL/min)¤§¦hµo©Ê°©Åè½F±wªÌªº¥þ¨暴露量¬Û¸û©ó年»´°·±d¨ü¸ÕªÌ¬ù°ª¥X60%¡C ¦P®Éµ¹¤©°·±d¨ü¸ÕªÌLenalidomide 25 mg ³æ¦¸¾¯量¤Î°ªªo¯×¿¯¹¡A·|降§C§l¦¬ªºµ{度¡A§Y¥þ¨暴露量(AUC)¬ù´î¤Ö20%¤Î¦å¤¤³Ì°ª¿@度(Cmax)´î¤Ö50%¡C¦b«Ø立Lenalidomide 療®Ä»P¦w¥þ©Êªº¸ÕÅç裡¡AÃĪ«ªºµ¹¤©µL»Ý¦Ò¼{¶i¹¡CLenalidomide ¥i»P¹ª«¨ÖªA©Î³æ¿W¨Ï¥Î¡C ¤À¥¬ Åé¥~¹êÅçÅã¥Ü¡A(14C)-lenalidomide »P¦å¼ß³J¥Õµ²¦Xªº¤ñ例¬ù¬°30%¡C¨C¤éµ¹¤©Lenalidomide 25 mg¡ALenalidomide ¦b精²G¤¤ªº¿@度¬°2 ¤p®É(1379 ng/³æ¦¸®g¥X)¤Î24 ¤p®É(35 ng/³æ¦¸®g¥X)¡C ¥NÁ ¶ÈLenalidomide ·|¶i¤J¥NÁ¡C¤HÅ餺´`Àôªºª«½è¥Dn¬OLenalidomide 쫬¡C兩Ó¤wª¾¥NÁª«¬°5-hydroxy-lenalidomide ¤ÎN-acetyl-lenalidomide¡F¦U§O¦b´`Àô¤¤¦û¦³ªº量都不¨ì¥ÀÃĪº5%¡C ±Æ°£ ¥Dn¬O¸g¥ÑµÇŦ±Æ°£¡C¥H¤fªA¤è¦¡§ë»P°·±d¨ü¸ÕªÌ[14C]-lenalidomide(25 mg)¡A10 ¤Ñ¤º¦b尿²G¤ÎÁT便Æ[¹î¨ìªº¬¡©Ê©ñ®g¾¯量¤À§O¬ù¬°90%¤Î4%¡C¦b24 ¤p®É¤º¡A¬ù¦³82%¬¡©Ê©ñ®g¾¯量¤À泌§elenalidomide¡C¨ä¤¤Hydroxy-lenalidomide ¤ÎN-acetyllenalidomide¤À§O¦û¤À泌量ªº4.59%¤Î1.83%¡Clenalidomide ¤§µÇŦ²M°£率¶W¹LµÇµ·²y¹L濾率¡CLenalidomide ªº¥§¡¥b°I´Á¡A°·±d¨ü¸ÕªÌ¬°3 ¤p®É¡A¦hµo©Ê°©Åè½F±wªÌ¬°3~5 ¤p®É¡C
|
°Æ§@¥Î |
|
³h¦å¡B©PÃä¤ô¸~¡B«K¯µ¡B¸¡Âm¡B©âµ¬¡C
|
¥æ¤¬§@¥Î |
|
¦P®ÉªA¥Î³æ¾¯©Î¦h¾¯dexamethasone(40 mg)不·|¹ïLenalidomide(25 mg)¦h¾¯量Ãİʾdzy¦¨¥ô¦ó臨§É¬ÛÃöªº¼vÅT¡CÅé¥~¸ÕÅç¡Alenalidomide ¬°¤@Ó¨ü½è¦ý不·|»PP-gp §í¨î¾¯µo¥Í§@¥Î¡C°·±d¦ÛÄ@¨ü¸ÕªÌªA¥Î¦h¾¯量P-gp §í¨î¾¯(¦pquinidine 600mg¡A¤@¤é兩¦¸)«á¡Aµ¹¤©Lenalidomide(25 mg)¡A¨Ã不·|³y¦¨Lenalidomide ¦å¤¤³Ì°ª¿@度(Cmax)¤Î¥þ¨ÃnÃÄ量(AUC)¦³臨§ÉÅãµÛ¼W¥[¡Cµ¹¤©°·±d¨ü¸ÕªÌP-gp §í¨î¾¯/¨ü½è(temsirolimus 25 mg)¤ÎLenalidomide(25 mg)¡A¨Ã不·|ÅãµÛ§ïÅÜLenalidomide¡Atemsirolimus ©Î¨ä¥NÁª«sirolimus ÃĪ«°Ê力¾Ç¡C
|
¸T§Ò |
|
1. Y©óÃh¥¥´Á¶¡ªA¥ÎLenalidomide¡A¥i¯à¾ÉPL¨à¥Íªø¯Ê³´¡C 2. Lenalidomide¸T¥Î©ó´¿¥X²{¹ïLenalidomideÄY«¹L±Ó(§Y¦åºÞ©Ê¤ô¸~¡A¥v¸¦¤å¥Í¤ó强¥Í¯gÔ¸s¡A¬r©Êªí¥Ö·»¸Ñ¯g)ªº¯f¤H¡C
|
µ¹¥I³W©w |
|
9.43 Lenalidomide(¦pRevlimid)¡G¡]101/12/1¡B106/10/1¡B109/2/1¡B109/8/1¡B112/4/1¡^ 1. ¥ý«e©|¥¼±µ¨ü¹L¥ô¦óªvÀø¥B¤£¾A¥Î³y¦å·F²ÓM²¾´Óªº¦hµo©Ê°©Åè½F±wªÌ¥i¨Ï¥Îlenalidomide¨Ö¥Îdexamethasone§@¬°²Ä¤@½uªvÀø¡C¶}©lªvÀø®É¯f±w¶·¦P®É²Å¦X¤U¦C(1)»P(2)ªº±ø¥ó¡G¡]109/2/1¡B109/8/1¡B112/4/1¡^ (1) °©Åè¼ß²ÓM(plasma cells)¤ñ¨Ò¡Ù10%¡A©Î¬O¸g¤Á¤ù½T»{¥B¦³¡Ù1Áûªºplasmacytoma¡C¡]112/4/1¡^ (2) ¥X²{¤U¦C¥ô¤@Á{§É¯gª¬¡G¡]112/4/1¡^ ¢¹.µÇ¥\¯à¤£¥þ¡Gserum creatinine¡Ö2.0mg/dL©Îestimated GFR (eGFR)¡Õ40 ml/min¡A¥BµL¨ä¥Lì¦]¥i¥H¸ÑÄÀ¡C ¢º.°ª¦å¶t(corrected serum calcium¡Ö11.0 mg/dL©Î2.75 mmol/L)¡C ¢».³h¦å(Hemoglobin¡Õ10 gm/dL ¥BµL¨ä¥Lì¦]¥i¥H¸ÑÄÀ)¡C ¢¾.¼v¹³Àˬd½T»{¤§osteolytic bone lesion(s)¡C ¢½.°©Åè¼ß²ÓM(plasma cells)¤ñ¨Ò¡Ù60% ¢¾.Serum free light-chain ratio¡Ù100¡C (3) ¨C4ÓÀøµ{«·s¥Ó½Ð®É¡A¶·«·sµû¦ô¬O§_¾A¦X±µ¨ü³y¦å·F²ÓM²¾´Ó¡CY¸g«·sµû¦ô¬°¤w¾A¦X±µ¨ü³y¦å·F²ÓM²¾´ÓªÌ¡A§Y¶·°±¤îRd¤§ªvÀø¡C¡]112/4/1¡^ 2. »Pdexamethasone¦X¨Ö¨Ï¥Î©ó¥ý«e¤w±µ¨ü¦Ü¤Ö¤@ºØªvÀø¥¢±Ñ¤§¦hµo©Ê°©Åè½F±wªÌ¡A¥B»Ý¦P®É²Å¦X¤U¦C(1)»P(2)ªº±ø¥ó¡G¡]101/12/1¡B112/4/1¡^ (1) ¨ã¦³¤U¦C¥ô¤@¯e¯f´c¤Æªº«ü¼Ð¡G ¯f±w¶}©lªvÀø«e¶·¦b³sÄò2¦¸µû¦ô¤¤§¡²Å¦X¦P¤@«ü¼Ð (¦ýY¬°plamacytoma Åé¿n¼W¥[¡A©Î¬O·s²£¥Íªºbone lesion(s)©Î·splasmacytoma¡A«h¶È»Ý1¦¸µû¦ô)¡G¡]112/4/1¡^ ¢¹.Y«e¤@½uªvÀø¤¤M component ³Ì§CÈ¡Ù5 g/dL¡A¦å²MM³J¥Õ»Ý¼W¥[¡Ù1 g/dL¡FY«e¤@½uªvÀø¤¤M component³Ì§CÈ¡Õ5 g/dL¡A¦å²MM³J¥Õ»Ý¼W¥[¡Ù0.5g/dL¡C ¢º.Urine M-protein»Ý¼W¥[¡Ù0.2 gm/24Hr¡A¥B»Ý¸û«e¤@½uªvÀø¤¤ªº³Ì§CȼW¥[¡Ù25%¡C ¢».¦bnon-secretary myeloma ¯f±w¡A°©Åè¼ß²ÓM (plasma cells)¤§¤ñ¨Òµ´¹ïȼW¥[¡Ù10%¡A¥B»Ý¸û«e¤@½uªvÀø¤¤ªº³Ì§CȼW¥[¡Ù25%¡C ¢¼.·s²£¥Íªºbone lesion(s)©Îplasmacytoma¡F¥B¶·¸g¯f²z¤Á¤ùÃÒ¹ê¡C ¢½.PlasmacytomaÅé¿n¼W¥[¡Ù50%¡C ¢¾.©PÃä¦å²G¤¤¼ß²ÓM¤ñ¨Ò¡Ù20%©Î¼ß²ÓMµ´¹ïÈ¡Ù2000 cells/£gL¡C (2) ¥X²{¤U¦C¥ô¤@Á{§É¯gª¬¡G¡]112/4/1¡^ ¢¹.·s²£¥Íªºbone lesion(s)©Îplasmacytoma¡F¥B¶·¸g¯f²z¤Á¤ùÃÒ¹ê¡C ¢º.Plasmacytoma Åé¿n¼W¥[¡Ù50%¡C ¢».°ª¦å¶t(corrected serum calcium¡Ö11.0 mg/dL ©Î 2.75 mmol/L)¡C ¢¼.³h¦å(Hemoglobin ¤U°´T«×¡Ù 2gm/dL¥BµL¨ä¥Lì¦]¥i¥H¸ÑÄÀ)¡C ¢½.µÇ¥\¯à´c¤Æ(eGFR»Ý¤U°´T«×¡Ù25%)¡A¥BµL¨ä¥Lì¦]¥i¥H¸ÑÄÀ¡C ¢¾.¥X²{¨ä¥L end-organ dysfunctions¡C 3.¶·¸g¨Æ«e¼f¬d®Öã«á¨Ï¥Î¡A¨C¦¸¥Ó½Ð¨Æ«e¼f¬d¤§Àøµ{¥H4ÓÀøµ{¬°¡A¨C4ÓÀøµ{¶·¦A¦¸¥Ó½Ð¡C (1)¨C¤Ñ¨Ï¥Î1²É¡C (2)¨Ï¥Î4ÓÀøµ{«á¡A¥²¶·½T©wparaprotein(M-protein)¥¼¤W¤É(§Yªí¥Ü¹ïÃĪ«¦³¤ÏÀ³©Î¬°Ã©wª¬ºA)©Î¹ï³¡¤Ànon-secretory type MM¯f¤H¥H°©ÅèÀˬdplasma cell¬°Àø®Ä¨Ì¾Ú¡A¤è¥iÄ~Äò¨Ï¥Î¡C 4. ¨C¤H²×¥Í¦Ü¦hµ¹¥I24ÓÀøµ{¬°¡]¨CÀøµ{¬°4¶g¡^¡C¡]106/10/1¡B109/2/1¡B109/8/1¡B112/4/1¡^ 5. 112¦~3¤ë31¤é¥H«e¤w®Ö©w¥ÎÃĤ§¯f¤H¡A±o¸g¨Æ«e¼f¬d®Öã«á¡A¨Ï¥Î¦ÜÁ`Àøµ{¤W ¡]§Y²×¥Í24ÓÀøµ{¡^©Î¨Ï¥Î´Á¶¡µo¥Í¯e¯f´c¤Æ¬°¤î¡C¡]112/4/1¡^
|
ª`·N¨Æ¶µ |
|
1. Lenalidomide¬OthalidomideÃþ¦üª«¥BÄY¸T©óÃh¥¥´Á¶¡¨Ï¥Î¡C 2. ¨ã¥Í¨|¯à¤O¤k©Ê¥²¶·¦Ó¥B¦b¶}©l±µ¨üLenalidomideªvÀøªº4¶g«e¡B¥ÎÃÄ´Á¶¡¡B¥ÎÃļȰ±´Á¶¡¡B¹ý©³°±ÃÄ«á4¬P´Á¤º¡AÁקKÃh¥¥¡C 3. Lenalidomide·|¦b±µ¨üªvÀø¤§¯f¤Hªººë²G¥X²{¡C±µ¨ü¥»«~ªvÀøªº¨k©Ê¤£¥i®½ºë¡C 4. ¯f¤HªA¥ÎLenalidomide´Á¶¡¤Î°±ÃÄ«á1Ӥ뤣±o®½¦å¡A¦]¬°¦å²G¦³¥i¯à³Qµ¹¤©Ãh¥¥°ü¤k¦Ó¨äFL¤£¥i¼ÉÅS©óLenalidomide¡C
|
ĵ»y |
|
·îL¡B¨ã¦å²G¾Ç¬r©Ê (¶Ý¤¤©Ê¥Õ¦å²y§C¤U¯g¤Î¦å¤pªO§C¤U)¡B²`³¡ÀR¯ß¦å®ê»PªÍ³¡¦å®ê¡C
|
¹L¶q³B²z |
|
¨S¦³¦hµo©Ê°©Åè½F±wªÌ¨Ï¥Î¹L量ªº¯S®í¸gÅç¡C¦b°·±d¨ü¸ÕªÌªº¾¯量½d³ò¸ÕÅç¡A´¿¦³¨Ï¥Î¹F200 mg(µ¹¤©100 mg¤@¤Ñ兩¦¸)¤Î³æ¾¯量¸ÕÅ禳¨Ç¨ü¸ÕªÌ´¿¨Ï¥Î°ª¹F400 mg¡C·kÄo¯g¡BëC³Â¯l¡B¬õ¯l¤Î¨xŦ»Ã¯À¤É°ª¬°¥Dn³q³øªº不良¤ÏÀ³¡C臨§É¸ÕÅç´Á¶¡¡A¾¯量¨î¬r©Ê¬°¶Ý¤¤©Ê¥Õ¦å´î¤Ö¤Î¦å¤pªO§C¤U¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
Àx¦s©ó25¢J ¥H¤U¡C
|